Paper of the month on Cardiovascular Pharmacotherapy

Published by the ESC Working Group on Cardiovascular Pharmacotherapy

This section includes a selection of interesting papers explained and commented by members of the Working Group on Cardiovascular Pharmacotherapy.

To submit a paper, get in touch with the Working Group nucleus 

Date

Title

• Date: 2025
  Title: Striking the balance between cardiac benefits and hepatic risks of lipid-lowering therapy
• Date: 2024
  Title: Body mass – a crucial consideration when prescribing antithrombotic therapy
• Date: 2024
  Title: Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
• Date: 2023
  Title: The ESC Working Group on Cardiovascular Pharmacotherapy
• Date: 2023
  Title: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
• Date: 2022
  Title: EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer
• Date: 2022
  Title: Cumulative evidence on DAPT: different strategies, heterogenous populations, complex decisions
• Date: 2021
  Title: Beta-blocker therapy after myocardial infarction guided by left ventricular ejection fraction: is 50 the new 40?
• Date: 2021
  Title: Wait a minute to prescribe off-label reduced dose of apixaban
• Date: 2021
  Title: Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity
• Date: 2021
  Title: From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents
• Date: 2021
  Title: Smoking and antiplatelet therapy after acute coronary syndromes
• Date: 2020
  Title: European Heart Journal – Cardiovascular Pharmacotherapy. Focus on subpopulations of atrial fibrillation patients
• Date: 2020
  Title: European Heart Journal – Cardiovascular Pharmacotherapy: Focus on antithrombotic treatments
• Date: 2020
  Title: European Heart Journal – Cardiovascular Pharmacotherapy. Focus on pharma in acute coronary syndrome: relationship between heparin dose and outcomes in MI patients undergoing PCI receiving P2Y12 inhibitors but not glycoprotein IIb/IIIa inhibitors.
• Date: 2019
  Title: Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System
• Date: 2019
  Title: High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality
• Date: 2019
  Title: External applicability of the COMPASS trial: the Western Denmark Heart Registry
• Date: 2019
  Title: Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54
• Date: 2019
  Title: Statin adherence in clinical trials